ClinConnect ClinConnect Logo
Search / Trial NCT03090516

Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Mar 23, 2017

Trial Information

Current as of July 21, 2025

Unknown status

Keywords

Ginkgo Biloba Dispersible Tablets Alzheimer's

ClinConnect Summary

The assessment of cognitive scales included Minimum Mental State Examination(MMSE), Alzheimer's Disease Assessment Scale-cognition(ADAS-cog), Neuropsychiatric inventory(NPI), quality of Life of Life in Alzheimer's disease(Qol-ADL), activities of Daily living(ADL), Geriatric Depression scale(GDS).Biochemical test included cholesterol, triglycerides, and low density lipoprotein.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. All patients were diagnosed with dementia caused by AD in 2011, the latest diagnostic criteria for Alzheimer's disease (NIA-AA), according to the patient's clinical and cranial imaging findings
  • 2. Improved Hachinski ischemic scale score \<4
  • 3. All patients underwent head CT and / or MRI examinations and laboratory tests to rule out other causes of dementia
  • 4. MMSE(High school≤24,Primary school≤20;illiteracy≤17)
  • 5. CDR 1-2
  • 6. The subjects and nurses signed informed consent, and the nursing staff were able to take responsibility for the supervision of the participants
  • 7. The subjects were stable
  • 8. Cooperate, willing to complete all parts of the research, and have the ability to complete the study alone or with the help of the nursing staff
  • 9. To cooperate with the study, do not live alone, such as living alone should keep in touch with the nurse every day.
  • Exclusion Criteria:
  • 1. Heart lung kidney disease, may interfere to evaluate the efficacy and safety of patients at risk or special disease,for example:Congestive heart failure et al.
  • 2. According to NINDS-AIREN standard (Roman GC et al 1993) is currently diagnosed as possible vascular dementia
  • 3. Improved Hachinski ischemic scale score(MHIS)≥4
  • 4. Diagnosis of severe depression, schizophrenia, and other major neurodegenerative disorders, according to the DSM-IV axis
  • 5. Neurological or other medical disorders that affect the function of the central nervous system,like Moderate anemia,Vitamin B12 or folic acid deficiency, et al. Not with the cognitive function examination (including blindness, deafness, severe language disorders).

About The First Affiliated Hospital With Nanjing Medical University

The First Affiliated Hospital of Nanjing Medical University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital is committed to implementing rigorous scientific methodologies to evaluate new therapies and treatment approaches. With a multidisciplinary team of experienced healthcare professionals and researchers, the hospital fosters a collaborative environment aimed at enhancing patient outcomes and contributing to the global medical community. Its strategic focus on translational medicine ensures that groundbreaking discoveries are efficiently translated into practical applications for patient care.

Locations

Nanjing, Jiangsu, China

Patients applied

0 patients applied

Trial Officials

Ting Wu

Study Director

The First Affiliated Hospital with Nanjing Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials